Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK: Funding For Second Kymriah Indication After Talks And Price Cut

Executive Summary

UK HTA body NICE says a second indication for Novartis’s groundbreaking CAR-T cell therapy Kymriah should be covered under the Cancer Drugs Fund.

You may also be interested in...



Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah

Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.

Scottish HTA Body OKs Vyxeos & Prevymis, But Rejects Kymriah In Lymphoma

The Scottish Medicines Consortium has OKd the use of two orphan drugs, Vyxeos for AML and Prevymis for preventing CMV reactivation, but rejected Novartis’s CAR-T therapy Kymriah, for use in lymphoma. 

Mixed HTA Results As Scotland Says No To Yescarta But Yes To Kymriah

The Scottish Medicines Consortium has recommended one CAR-T therapy, Novartis’ Kymriah, for use on Scotland’s National Health Service but rejected another, Gilead’s Yescarta, claiming the company has failed to prove it would be cost-effective.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS124675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel